<DOC>
	<DOCNO>NCT00739375</DOCNO>
	<brief_summary>Pulmonary hypertension ( PHT ) elevation pulmonary arterial pressure ( PAP ) result heart , lung systemic disease . PHT also complicate chronic hemodialysis ( HD ) therapy immediately creation arteriovenous ( AV ) access , even start HD therapy . It tend regress temporary AV access closure successful kidney transplantation . Affected patient significantly high cardiac output . This syndrome associate statistically significant survival disadvantage . The laboratory hallmark syndrome reduce basal stimulatory nitric oxide ( NO ) level . It appear patient end-stage renal disease ( ESRD ) acquire endothelial dysfunction reduces ability pulmonary vessel accommodate AV access-mediated elevate cardiac output , exacerbate PHT . Doppler echocardiographic screen ESRD patient schedule HD therapy occurrence PH indicate . Early diagnosis enable timely intervention , currently limit change dialysis modality peritoneal dialysis refer kidney transplantation.An echocardiographic diagnosis pulmonary hypertension ( PHT ) make systolic pulmonary arterial pressure ( PAP ) exceed normal value ( 30 mmHg ) . In mild PHT , PAP value range 45 mmHg , moderate PHT , PAP 45 65 mmHg , severe PHT , PAP value great 65 mmHg . Systolic PAP equal cardiac output time pulmonary vascular resistance ( PVR ) , ( i.e. , PAP = cardiac output Ã— PVR ) . Increased cardiac output cause PH enormous capacity pulmonary circulation accommodate increase blood flow . Therefore development PHT require pathologic , marked elevation pulmonary vascular resistance . The presence PH may reflect serious pulmonary vascular disease , progressive fatal . Consequently , accurate diagnosis cause PHT essential order establish effective treatment program . Pulmonary hypertension occur diverse etiology . In 1996 first note unexplained PH long-term hemodialysis ( HD ) patient epidemiologic study disorder ( Nakhoul F Yigla M Rambam Medical Cemter-Haifa ) . It assume PHT relate end-stage renal disease ( ESRD ) long-term HD therapy via arteriovenous ( AV ) access . There several potential explanation development PHT patient ESRD . Hormonal metabolic derangement associate ESRD might lead vasoconstriction pulmonary vessel increase pulmonary vascular resistance . Values PAP may increase high cardiac output result AV access , worsen commonly occur anemia fluid overload . Despite almost five decade HD therapy via surgically create , often large , hemodynamically significant AV access long-term impact intervention pulmonary circulation receive little attention . RD versus AV HD via AV access Proposed Mechanisms : 1 . Elevated Parathyroid hormone 2 . Metastatic Calcification due increase calcium-phosphor multiple 3 . High cardiac output 4 . Nitric oxide-endothelin metabolism 5 . A-v Access flow These observation indicate role AV access-mediated elevation cardiac output pathogenesis PH . The correlation access flow PAP value yet study . Since patient undergo HD therapy via AV access PH reverse successful kidney transplantation short AV access compression , conclude ESRD AV access-mediated elevate cardiac output require development PH . From physiologic point view , due enormous capacity pulmonary microcirculation , increase cardiac output cause PH . It inability pulmonary circulation ESRD patient accommodate AV access-mediated elevate cardiac output lead development PH .</brief_summary>
	<brief_title>The Effect Blood Flow Maturing Arteriovenous Access Hemodialysis Development Pulmonary Hypertension .</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>All new primary av access Preoperatively know pulmonary hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Influence</keyword>
	<keyword>av access</keyword>
	<keyword>flow</keyword>
	<keyword>development</keyword>
</DOC>